tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Yamada H et al. Simvastatin-tacrolimus and simvastatin-cyclosporin interactions in rats. 1998 Biopharm Drug Dispos pmid:9673778
Trindade E et al. Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation. 1998 J. Hepatol. pmid:9672183
Polak J et al. Primary pulmonary hypertension: pathologist as patient. 1998 May-Jun J R Coll Physicians Lond pmid:9670148
Gross A et al. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. 1998 EMBO J. pmid:9670005
Takamatsu Y et al. IL-13 production by peripheral blood mononuclear cells from patients with atopic dermatitis. 1998 Dermatology (Basel) pmid:9669111
Horigome A et al. Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells. 1998 Immunopharmacology pmid:9667420
Romero E et al. [Tacrolimus and hypertrophic cardiomyopathy]. 1998 Med Clin (Barc) pmid:9666425
Morris-Stiff G et al. Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transpl. Int. pmid:9665010
Peter C et al. Does tacrolimus cause more severe anemia than cyclosporine A in children after renal transplantation? 1998 Transpl. Int. pmid:9665008
Zhang JG et al. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation. 1998 Transpl. Int. pmid:9665007
Charco R et al. Early use of tacrolimus as rescue therapy for refractory liver allograft rejection. 1998 Transpl. Int. pmid:9665004
Horimoto H et al. Transplantation tolerance by a combined therapy with sulfatide, anti-LFA-1/ICAM-1 monoclonal antibodies and FK506 in rat cardiac transplantation. 1998 Transpl. Int. pmid:9665003
Jara P et al. Tacrolimus for steroid-resistant liver rejection in children. 1998 Transpl. Int. pmid:9664996
Reggiani P et al. Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: experience in 20 children. 1998 Transpl. Int. pmid:9664995
Pou L et al. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. 1998 Transpl. Int. pmid:9664994
Margarit C et al. Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. 1998 Transpl. Int. pmid:9664992
Hernández-Herrera G et al. Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. 1998 Transpl. Int. pmid:9664956
Kyo M et al. Morphological findings in non-episode biopsies of kidney transplant allografts treated with FK506 or cyclosporine. 1998 Transpl. Int. pmid:9664955
Morris-Stiff G et al. Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome. 1998 Transpl. Int. pmid:9664954
Morris-Stiff G et al. Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection. 1998 Transpl. Int. pmid:9664949
Hauser IA and Neumayer HN Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. 1998 Transpl. Int. pmid:9664948
Kokado Y et al. Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. 1998 Transpl. Int. pmid:9664945
Stockwell BR and Schreiber SL TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. 1998 Chem. Biol. pmid:9662508
Nagayasu T et al. Expression of proliferating cell nuclear antigen in bronchial epithelium after lung transplantation in the rat. 1998 J. Heart Lung Transplant. pmid:9662091
Lai MM et al. Cain, a novel physiologic protein inhibitor of calcineurin. 1998 J. Biol. Chem. pmid:9660798
Tsujikawa A et al. Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. 1998 Stroke pmid:9660400
Bader G et al. Reduction of cyclosporine-induced gingival overgrowth following a change to tacrolimus. A case history involving a liver transplant patient. 1998 J. Periodontol. pmid:9660343
McBride WJ et al. Allogeneic fetal intestinal transplantation with FK506 immunosuppression. 1998 J. Pediatr. Surg. pmid:9660232
Fujino T et al. The immunosuppressive compound FK506 does not affect expulsion of Echinostoma trivolvis in C3H mice. 1998 Parasitol. Res. pmid:9660146
Le Bihan S et al. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. 1998 Mol. Endocrinol. pmid:9658403
Sasa H et al. Hepatic extraction of tacrolimus in rats with experimental liver diseases. 1998 Biol. Pharm. Bull. pmid:9657047
Nishioka T et al. [Is tacrolimus effective for ongoing renal allograft rejection?]. 1998 Hinyokika Kiyo pmid:9656112
Morozumi K et al. [Current topics of the rejection pathology in human renal allografts]. 1998 Hinyokika Kiyo pmid:9656109
Tamura K [Multiple actions of tacrolimus and cyclosporin A as specific inhibitors of calcineurin]. 1998 Tanpakushitsu Kakusan Koso pmid:9655970
Matsui H et al. [Physiological role of calcineurin in central nervous system]. 1998 Tanpakushitsu Kakusan Koso pmid:9655961
Cetinkale O et al. Involvement of neutrophils in ischemia-reperfusion injury of inguinal island skin flaps in rats. 1998 Plast. Reconstr. Surg. pmid:9655420
Kommers T et al. Regulation of the phosphorylation of glial fibrillary acidic protein (GFAP) by glutamate and calcium ions in slices of immature rat spinal cord: comparison with immature hippocampus. 1998 Neurosci. Lett. pmid:9654363
Tarumi K et al. The plasma FK506-binding protein 12 level is related to acute cellular rejection in small bowel transplantation. 1998 Immunopharmacol Immunotoxicol pmid:9653668
Friberg H et al. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. 1998 J. Neurosci. pmid:9651198
Canzanello VJ et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). 1998 Liver Transpl Surg pmid:9649648
Gabe SM et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. 1998 Gastroenterology pmid:9649460
Gruessner RW et al. Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. 1998 Clin Transplant pmid:9642520
Kuwata T et al. A role of calcineurin in coreceptor regulation during differentiation of Cd4+Cd8+ T cells. 1998 Biochem. Biophys. Res. Commun. pmid:9642110
Murray M et al. Comparison of tacrolimus absorption in transplant patients receiving continuous versus interrupted enteral nutritional feeding. 1998 Ann Pharmacother pmid:9640479
Morris-Stiff G and Jurewicz WA Single centre experience with mycophenolate mofetil for refractory rejection in cadaveric renal transplantation. 1998 Transpl. Int. pmid:9638849
Takahara S et al. A comparative study of FK506 granules and capsules in renal transplant recipients. 1998 Transpl. Int. pmid:9638846
Abraham RT Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. 1998 Curr. Opin. Immunol. pmid:9638370
Baldari CT et al. NF-AT-luciferase reporter T cell lines as tools to screen immunosuppressive drugs. 1998 Biologicals pmid:9637743
Resch K and Szamel M Molecular mechanisms of the immunosuppressive action of cyclosporin A. 1997 Sep-Oct Int. J. Immunopharmacol. pmid:9637358
Schneeberger H et al. Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center. 1998 Transplant. Proc. pmid:9636642
Gerber DA et al. Immunosuppressive agents: recent developments in molecular action and clinical application. 1998 Transplant. Proc. pmid:9636637
Goulet O et al. Small bowel transplantation alone or with the liver in children: changes by using FK506. 1998 Transplant. Proc. pmid:9636636
Stratta RJ Late acute rejection episodes after vascularized pancreas transplantation. 1998 Transplant. Proc. pmid:9636633
Gruessner RW Antibody induction therapy in pancreas transplantation. 1998 Transplant. Proc. pmid:9636632
Burke GW et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. 1998 Transplant. Proc. pmid:9636627
Peddi VR et al. Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9636626
Bruce DS et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9636625
Ciancio G et al. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. 1998 Transplant. Proc. pmid:9636624
Schulz T et al. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. 1998 Transplant. Proc. pmid:9636623
Walker S et al. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. 1998 Transplant. Proc. pmid:9636618
Wiebe K et al. FK506 rescue therapy in lung transplantation. 1998 Transplant. Proc. pmid:9636613
Lipson DA et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. 1998 Transplant. Proc. pmid:9636612
McAlister VC et al. Cost of liver transplantation using tacrolimus. 1998 Transplant. Proc. pmid:9636611
Mueller AR et al. Influence of immunosuppression on patient outcome after liver transplantation. 1998 Transplant. Proc. pmid:9636608
Maggard M et al. Incidence of acute rejection in African-American liver transplant recipients. 1998 Transplant. Proc. pmid:9636607
Charco R et al. Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636605
Nakamura M et al. Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. 1998 Transplant. Proc. pmid:9636600
Ghobrial RM et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. 1998 Transplant. Proc. pmid:9636597
Platz KP et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. 1998 Transplant. Proc. pmid:9636596
Lang M et al. Impact of immunosuppression in liver transplantation across a positive crossmatch. 1998 Transplant. Proc. pmid:9636595
Mueller AR et al. Does initial graft function influence the outcome after liver transplantation? 1998 Transplant. Proc. pmid:9636594
Cantarovich M et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. 1998 Transplant. Proc. pmid:9636592
Bekersky I et al. Bioequivalence of a new strength tacrolimus capsule under development. 1998 Transplant. Proc. pmid:9636591
Liu WT et al. In vitro generation of tacrolimus metabolites and their detection in whole blood. 1998 Transplant. Proc. pmid:9636590
Steinmueller T et al. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. 1998 Transplant. Proc. pmid:9636589
Klupp J et al. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. 1998 Transplant. Proc. pmid:9636585
Abe M et al. Successful prednisone withdrawal after living-related liver transplantation. 1998 Transplant. Proc. pmid:9636584
Langrehr JM et al. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. 1998 Transplant. Proc. pmid:9636583
Bilbao I et al. Experience with neoral cyclosporine through the oral route in liver transplantation. 1998 Transplant. Proc. pmid:9636580
Pratschke J et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results. 1998 Transplant. Proc. pmid:9636575
Rudich SM et al. Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. 1998 Transplant. Proc. pmid:9636574
Ringe B et al. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. 1998 Transplant. Proc. pmid:9636573
Cai TH et al. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636572
Taibi A et al. Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. 1998 Transplant. Proc. pmid:9636571
Platz KP et al. FK506 for primary and rescue therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636570
Millis JM et al. Successful use of tacrolimus for initial rejection episodes after liver transplantation. 1998 Transplant. Proc. pmid:9636569
Zervos XA et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplant. Proc. pmid:9636568
Jain A et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. 1998 Transplant. Proc. pmid:9636567
Van Buren D et al. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). 1998 Transplant. Proc. pmid:9636566
Wiesner RH Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. 1998 Transplant. Proc. pmid:9636565
McDiarmid S et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636564
Samuel D et al. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636563
Rossi G et al. Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. 1998 Transplant. Proc. pmid:9636562
Grewal HP et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. 1998 Transplant. Proc. pmid:9636558
Shapiro R et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. 1998 Transplant. Proc. pmid:9636557
Fitzsimmons WE et al. Demographic considerations in tacrolimus pharmacokinetics. 1998 Transplant. Proc. pmid:9636552
Neylan JF Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636551
Kumar MS et al. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. 1998 Transplant. Proc. pmid:9636549
Undre NA et al. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. 1998 Transplant. Proc. pmid:9636527
Woodle ES et al. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. 1998 Transplant. Proc. pmid:9636526